Samuel Quentin
Overview
Explore the profile of Samuel Quentin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
738
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bercier P, Wang Q, Zang N, Zhang J, Yang C, Maimaitiyiming Y, et al.
Cancer Discov
. 2023 Sep;
13(12):2548-2565.
PMID: 37655965
Significance: Arsenic curative effects in APL rely on PML targeting. We report a PML B-box-2 structure that drives trimer assembly, positioning a cysteine trio to form an arsenic-binding pocket, which...
2.
Sebert M, Gachet S, Leblanc T, Rousseau A, Bluteau O, Kim R, et al.
Cell Stem Cell
. 2023 Feb;
30(2):153-170.e9.
PMID: 36736290
Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical,...
3.
Tessier S, Ferhi O, Geoffroy M, Gonzalez-Prieto R, Canat A, Quentin S, et al.
Nat Commun
. 2023 Jan;
14(1):124.
PMID: 36624101
No abstract available.
4.
Tessier S, Ferhi O, Geoffroy M, Gonzalez-Prieto R, Canat A, Quentin S, et al.
Nat Commun
. 2022 Sep;
13(1):5726.
PMID: 36175410
Membrane-less organelles are condensates formed by phase separation whose functions often remain enigmatic. Upon oxidative stress, PML scaffolds Nuclear Bodies (NBs) to regulate senescence or metabolic adaptation. PML NBs recruit...
5.
Passet M, Kim R, Gachet S, Sigaux F, Chaumeil J, Galland A, et al.
Blood
. 2022 Mar;
139(24):3505-3518.
PMID: 35316324
Oncogenic alterations underlying B-cell acute lymphoblastic leukemia (B-ALL) in adults remain incompletely elucidated. To uncover novel oncogenic drivers, we performed RNA sequencing and whole-genome analyses in a large cohort of...
6.
Wu H, Rerolle D, Berthier C, Hleihel R, Sakamoto T, Quentin S, et al.
Cancer Discov
. 2021 Jul;
11(12):3198-3213.
PMID: 34301789
Significance: ActD induces complete remissions in NPM1-mutant AMLs. We found that NPM1c affects mitochondrial biogenesis and PML NBs. ActD targets mitochondria, yielding ROS which enforce PML NB biogenesis and restore...
7.
Cerrano M, Duchmann M, Kim R, Vasseur L, Hirsch P, Thomas X, et al.
Leukemia
. 2020 Jun;
35(3):712-723.
PMID: 32581253
Intra-tumor heterogeneity portends poor outcome in many cancers. In AML, a higher number of drivers worsens prognosis. The Shannon Index is a robust metric of clonal heterogeneity that accounts for...
8.
Masse A, Roulin L, Pasanisi J, Penneroux J, Gachet S, Delord M, et al.
Leuk Res
. 2019 Nov;
87:106269.
PMID: 31751766
Bromodomain and Extra-Terminal inhibitors (BETi) such as OTX015 are active in Acute Myeloid Leukaemias (AML). Their activity on Leukemic Stem Cells (LSCs) is less documented. We interrogated the anti-LSC activity...
9.
Sebert M, Passet M, Raimbault A, Rahme R, Raffoux E, Sicre de Fontbrune F, et al.
Blood
. 2019 Sep;
134(17):1441-1444.
PMID: 31484648
Germline DDX41 mutations are involved in familial myelodysplastic syndromes (MDSs) and acute myeloid leukemias (AMLs). We analyzed the prevalence and characteristics of DDX41-related myeloid malignancies in an unselected cohort of...
10.
Sarasin A, Quentin S, Droin N, Sahbatou M, Saada V, Auger N, et al.
Blood
. 2019 Mar;
133(25):2718-2724.
PMID: 30914417
No abstract available.